)
Edge23 Jan 2026
Death, Taxes, and Garbage: The Story of WM
How Waste Management turned garbage into one of America's most stable business models through landfills, regulation, and nationwide scale.
Chugai Pharmaceutical
Chugai Pharmaceutical (4519) investor relations material
Chugai Pharmaceutical Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary29 Jan, 2026
Executive summary
Achieved record-high revenue of JPY 1,257.9 billion in FY2025, with operating profit reaching JPY 623.2 billion and net income at JPY 451.0 billion, driven by strong domestic and overseas sales, especially Hemlibra and Actemra exports.
Operating profit margin reached a record 49.5%, with core net income increasing for the ninth consecutive year.
Management expects another year of record-breaking results in 2026, with revenue forecasted at JPY 1,345 billion and core operating profit at JPY 670 billion.
Growth is supported by domestic sales, increased royalty and profit-sharing income, and a focus on new and mainstay products.
Special dividends were paid for the 100th anniversary, resulting in a high payout ratio for 2025.
Financial highlights
Pharmaceutical product sales rose 8.0% year-on-year to JPY 1,077.8 billion; domestic sales up 2.5% to JPY 472.4 billion and overseas sales up 12.8% to JPY 605.4 billion.
Other revenues, including royalties, increased to JPY 180.1 billion, mainly from Hemlibra royalties.
Cost of sales ratio for pharmaceutical products improved by 1.3 percentage points to 32.6%.
R&D expenses rose to JPY 180.1 billion, mainly due to yen depreciation and ongoing investment in drug discovery.
Earnings per share (basic) increased to JPY 263.73, with core EPS projected at JPY 295.00 for 2026.
Outlook and guidance
FY2026 revenue projected to grow 6.9% year-on-year to JPY 1,345 billion; core operating profit to rise 7.5% to JPY 670 billion; core net income to reach JPY 485.0 billion.
Domestic product sales expected to increase, offsetting NHI price revisions and generic competition, while overseas sales are projected to remain flat.
Other revenues to increase significantly, driven by higher royalties and milestone payments from Lunsumio, Orforglipron, and Hemlibra.
Ordinary dividend for 2026 forecasted at JPY 132 per share, up JPY 10 from 2025, with a payout ratio of 44.7%.
Strategic focus on accelerating R&D, digital transformation, and global product launches to achieve sustainable growth.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Chugai Pharmaceutical earnings date
Q1 202624 Apr, 2026
Chugai Pharmaceutical
Next Chugai Pharmaceutical earnings date
Q1 202624 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Chugai Pharmaceutical Co., Ltd., operating under the umbrella of F. Hoffmann-La Roche Ltd, is a notable player in the pharmaceutical industry, mainly in Japan. Chugai is dedicated to the research, development, commercialization, and manufacture of biopharmaceuticals and therapeutic antibodies. The company's product range focuses on several therapeutic areas such as cancer, bone and joint diseases, renal diseases, and immune disorders, among others. It also plays a significant role in the global healthcare market through its international operations in North America, Europe, and other regions in Asia. Chugai Pharmaceutical is headquartered in Tokyo, Japan, and its shares are listed on the Tokyo Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage